Raymond James Upgrades Medexus Pharmaceuticals (TSE:MDP) to Strong-Buy

Raymond James upgraded shares of Medexus Pharmaceuticals (TSE:MDP) from an outperform rating to a strong-buy rating in a research note issued to investors on Wednesday,BayStreet.CA reports. The firm currently has C$4.00 price target on the stock.

A number of other research firms have also commented on MDP. Leede Financial set a C$8.25 price target on Medexus Pharmaceuticals and gave the company a “speculative buy” rating in a research report on Monday, September 30th. Alliance Global Partners raised shares of Medexus Pharmaceuticals to a “strong-buy” rating in a research report on Monday, December 23rd. Two analysts have rated the stock with a buy rating and four have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Strong Buy” and an average target price of C$5.25.

Medexus Pharmaceuticals Stock Performance

Shares of MDP opened at C$3.60 on Wednesday. The firm has a market capitalization of C$88.31 million, a P/E ratio of 72.00 and a beta of 1.96. Medexus Pharmaceuticals has a 52 week low of C$1.47 and a 52 week high of C$3.60. The stock has a 50 day moving average price of C$2.72 and a two-hundred day moving average price of C$2.50.

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.